This kind of tool enables breeders to work proactively to identify diseases in their litters. Ultimately it can help them to make informed choices and may reduce the likelihood of producing kittens with preventable genetic diseases.

Genetics can provide breeders with the tools to enable smarter and more sustainable breeding decisions. Our hope in the cat breeding community is that through this kind of advanced testing, they will be able to increase their breed’s genetic diversity.

We are very excited to be working with Genoscoper on the new Optimal Selection™ breeder test. Our hope is that through this advanced testing, breeders will be able to increase their breed’s genetic diversity, while keeping unwanted diseases out of the future generations. Our aim is to provide breeders with the tool to enable smarter and more sustainable breeding decisions through genetics.

The mutations linked to hundreds of inherited diseases and the genes associated with specific phenotypic traits have been identified and can easily be screened for in one test panel.

This kind of tool enables veterinarians to proactively identify diseases in their patients and assist breeders to gain objective information about the dogs in their breeding program. Ultimately it helps them to make informed choices and reduce the likelihood of producing puppies with preventable genetic diseases.

DNA repair mechanism research is crucial to our understanding of Lynch syndrome cancer development. Last week, the Nobel Prize in Chemistry 2015 was awarded to three researchers for having mapped, at a molecular level, how cells repair damaged DNA and safeguard the genetic information.

We are happy to be able to utilize this groundbreaking research and apply it to preventive health care.

Lynch Syndrome associated cancer diagnostics market is valued at 35 billion USD with 7.5% CAGR expected. Especially the volumes of predictive screening methods for detecting inherited cancer-causing conditions have been growing due to their nature of supporting preventive care as they can potentially reduce the overall health care costs significantly.

We are aiming at commercializing DiagMMR™ in 2017 and expect wide market adaptation, for it is the only functional test available to diagnose this complex syndrome with high cancer risk.

The decision Helsinki made serves to reinforce our confidence in our ability to provide the most advanced LED luminaires on the market. We work hard to ensure the high quality of our Finnish made products and envision executing similar projects for many more cities, both in Finland and abroad, in the near future.

The market for LED luminaires is currently growing at an annual rate of 20 %. The Sirius outdoor luminaire is a great example of successful Finnish product that is based on sustainable development and advanced technology.

We believe in profitability and business growth based on domestic production.

MyDogDNA testing concept is very versatile and can be used for various purposes by veterinary practitioners and animal owners alike. In the short term, the partnership with Mars Veterinary enables us to reach over 90 % of veterinary clinics on a global scale.

Genoscoper and Mars Veterinary share mutual interests and future visions for advancing animal health and welfare. Our partnership is a clear demonstration not only of Genoscoper’s expertise and dedication but also of the high quality of Finnish DNA technology in general. For Genoscoper, this is an important step on our path of becoming the leading DNA diagnostics company for all companion animals.

This new partnership between Mars Veterinary and Genoscoper will allow Mars Petcare globally to build upon Mars’s United States based leadership in canine DNA testing. We hope it will lead to global next-generation solutions for dogs, owners, veterinarians and breeders.

By combining our efforts, we will bring more advanced, accurate, and relevant DNA tests quicker across the globe, which ultimately means many more dogs and owners will have better relationships. We look forward to working with the team at Genoscoper going forward.